p1

Cambridge Healthtech Institute’s Inaugural

Lead and Candidate Selection for Therapeutic Proteins
( 治療用蛋白質的先導化合物和藥劑候補選擇 )

Strategies and Best Practices for Key Early Decision Gates

1月21日~22日

Part of the Protein Engineering & Development pipeline

The screenings and studies that comprise a company's lead and candidate selection funnel are an essential stage of biopharmaceutical R&D. Good selections not only ensure that the best quality molecules are chosen for advancement, but that these match target profile for efficacy, safety, and pharmacology. PepTalk's new Lead and Candidate Selection for Therapeutic Proteins meeting presents a wide range of strategies, models and technologies used for these evaluations, and considers the best practices in this field. Case studies from both large and small organizations will showcase the innovative ways organizations have employed these tools to help ensure rapid progression through subsequent development steps and the prospects for success in the clinic.

Preliminary Agenda

KEYNOTE PRESENTATION: Talk Title to be Announced

Peter M. Tessier, PhD, Professor, Pharmaceutical Sciences and Chemical Engineering, University of Michigan

IMPROVING THE QUALITY OF LEAD AND CANDIDATE SELECTIONS

Designing Better Therapeutics by Uncovering Footprint on Cynomolgus Ortholog of the Target

Ramkrishna (Ramu) Sadhukhan, PhD, Principal Research Scientist, Global Protein Sciences, AbbVie Bioresearch Center

Identification of Specific Regions of Glycoproteins to Elicit Early Antibody Progenitors for Lassa Vaccine Design

Kate Hastie, PhD, Instructor, La Jolla Institute for Immunology

Chemical Liability Analysis of the Therapeutic Antibody Sequence Landscape

Max Vásquez, PhD, Head, Computational Biology, Adimab

SAFETY AND EFFICACY PREDICTION

Improving Understandings of Drug Biology to Optimize Engineering of Molecules with Complex Modes of Action

Hubert Kettenberger, PhD, Senior Principal Scientist, Protein Engineering, Roche, Germany

In vitro Assays for Predictive Assessment of Immunogenicity of Biotherapeutics

Vibha Jawa, PhD, Director, Risk Assessment and Clinical Immunogenicity, Merck

LEAD CHARACTERIZATION AND LIABILITY MITIGATION

Robust Computational Algorithms for the Rational Design of Functional de novo Proteins

Daniel-Adriano Silva, PhD, Translational Investigator, Baker Lab, University of Washington

Quest for Quality Drug: The Application of Early Screening Biophysical Assays to Select Manufacturable Molecules

Sathya Venkataramani, PhD, Associate Director, Biophysics, Janssen Biotherapeutics

Preemptive Mitigation of Biotherapeutic Immunogenicity via Optimized Library Design

Karl Griswold, PhD, Associate Professor, Engineering, Dartmouth College

An in vitro Transcytosis Assay for Predicting in vivo Clearance of Therapeutic Antibodies in Humans

Chang Liu, PhD, Associate Scientist, Biochemical and Cellular Pharmacology, Genentech

Selection and Characterization of a Lead Antibody for an Antibody Drug Conjugate to Achieve Non-Genotoxic Conditioning for Bone Marrow Transplant

Rajiv Panwar, PhD, Principal Scientist, Magenta Therapeutics

IMPROVING THE QUALITY OF DEVELOPABILITY PREDICTION

Benchmarking to Validate Developability Risk Assessment

Jonathan Kingsbury, PhD, Senior Director, Developability & Preformulation Science, Sanofi

Improved AC-SINS Assay to Remove the Hurdles of Salt Dependency in Formulation Screening

Samantha Phan, Consultant Biologist, Protein BioSciences, Eli Lilly and Company



* 活動內容有可能不事先告知作更動及調整。

Choose your language
Chinese
Japanese
Korean
English






2020年會議節目和培訓研討會


免費電子郵件通知服務